Literature DB >> 20014866

Evaluation of di-sansalvamide A derivatives: synthesis, structure-activity relationship, and mechanism of action.

Leslie D Alexander1, Robert P Sellers, Melinda R Davis, Veronica C Ardi, Victoria A Johnson, Robert C Vasko, Shelli R McAlpine.   

Abstract

Described is the SAR of 18 di-sansalvamide A derivatives and the mechanism of action of the most potent compound. We show that this scaffold is a promising lead in the development of novel cancer therapeutics because it is cytotoxic at nanomolar potency, inhibits a well-established oncogenic target (Hsp90), and does not share structural motifs with current drugs on the market.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 20014866      PMCID： PMC2805559          DOI： 10.1021/jm901566c

Source DB:  PubMed          Journal:  J Med Chem        ISSN： 0022-2623            Impact factor:   7.446


  17 in total

1.  HSP90 regulates cell survival via inositol hexakisphosphate kinase-2.

Authors:  Anutosh Chakraborty; Michael A Koldobskiy; Katherine M Sixt; Krishna R Juluri; Asif K Mustafa; Adele M Snowman; Damian B van Rossum; Randen L Patterson; Solomon H Snyder
Journal:  Proc Natl Acad Sci U S A       Date:  2008-01-14       Impact factor: 11.205

Review 2.  Conformationally based design of macrocycles as antitumor agents.

Authors:  Erinprit K Singh; Robert P Sellers; Leslie D Alexander; Shelli R McAlpine
Journal:  Curr Opin Drug Discov Devel       Date:  2008-07

3.  The conformation of cyclo(-D-Pro-Ala4-) as a model for cyclic pentapeptides of the DL4 type.

Authors:  Markus Heller; Martin Sukopp; Natia Tsomaia; Michael John; Dale F Mierke; Bernd Reif; Horst Kessler
Journal:  J Am Chem Soc       Date:  2006-10-25       Impact factor: 15.419

Review 4.  Novobiocin and additional inhibitors of the Hsp90 C-terminal nucleotide-binding pocket.

Authors:  Alison Donnelly; Brian S J Blagg
Journal:  Curr Med Chem       Date:  2008       Impact factor: 4.530

Review 5.  The heat shock protein 90 chaperone complex: an evolving therapeutic target.

Authors:  M F Barginear; C Van Poznak; N Rosen; S Modi; C A Hudis; D R Budman
Journal:  Curr Cancer Drug Targets       Date:  2008-09       Impact factor: 3.428

6.  A phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with hormone-refractory metastatic prostate cancer.

Authors:  Elisabeth I Heath; David W Hillman; Ulka Vaishampayan; Shijie Sheng; Fazlul Sarkar; Felicity Harper; Melvin Gaskins; Henry C Pitot; Winston Tan; S Percy Ivy; Roberto Pili; Michael A Carducci; Charles Erlichman; Glenn Liu
Journal:  Clin Cancer Res       Date:  2008-12-01       Impact factor: 12.531

Review 7.  Dimeric approaches to anti-cancer chemotherapeutics.

Authors:  M K Hadden; B S J Blagg
Journal:  Anticancer Agents Med Chem       Date:  2008-10       Impact factor: 2.505

8.  Phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with metastatic melanoma.

Authors:  David B Solit; Iman Osman; David Polsky; Katherine S Panageas; Adil Daud; James S Goydos; Jerrold Teitcher; Jedd D Wolchok; F Joseph Germino; Susan E Krown; Daniel Coit; Neal Rosen; Paul B Chapman
Journal:  Clin Cancer Res       Date:  2008-12-15       Impact factor: 12.531

9.  Synthesis and cytotoxicity of a new class of potent decapeptide macrocycles.

Authors:  Melinda R Davis; Thomas J Styers; Rodrigo A Rodriguez; Po-Shen Pan; Robert C Vasko; Shelli R McAlpine
Journal:  Org Lett       Date:  2007-12-21       Impact factor: 6.005

10.  Mechanism of dimer formation of the 90-kDa heat-shock protein.

Authors:  T Nemoto; Y Ohara-Nemoto; M Ota; T Takagi; K Yokoyama
Journal:  Eur J Biochem       Date:  1995-10-01
View more
  3 in total

Review 1.  Macrocyclic inhibitors of hsp90.

Authors:  Victoria A Johnson; Erinprit K Singh; Lidia A Nazarova; Leslie D Alexander; Shelli R McAlpine
Journal:  Curr Top Med Chem       Date:  2010       Impact factor: 3.295

2.  18F-labeled Dimer-Sansalvamide A Cyclodecapeptide: A Novel Diagnostic Probe to Discriminate Pancreatic Cancer from Inflammation in a Nude Mice Model.

Authors:  Xiaohui Wang; Jun Zhang; Zhijian Han; Liheng Ma; Yumin Li
Journal:  J Cancer       Date:  2022-03-21       Impact factor: 4.207

3.  Solid phase versus solution phase synthesis of heterocyclic macrocycles.

Authors:  Seong Jong Kim; Shelli R McAlpine
Journal:  Molecules       Date:  2013-01-16       Impact factor: 4.411
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.